Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy

被引：0
|
作者：
Ellsworth, Patrick [1 ,2 ]
Chen, Sheh-Li [3 ]
Key, Nigel [1 ]
Abajas, Yasmina [2 ]
Ma, Alice [1 ]
机构：
[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Houpt Bldg,CB 7305,170 Manning Dr,3rd Floor, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Div Pediat Hematol Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 01期
关键词：
OBI-1; SEQUENCE; SAFETY;
D O I：
10.1111/hae.14111
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E147 / E150
页数：4
相关论文
共 33 条
  • [21] Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A
    Sattler, Laurent
    Raissi, Ahlem
    Fornoff, Damien
    Gerout, Anne-Cecile
    Feugeas, Olivier
    Grunebaum, Lelia
    Desprez, Dominique
    ANNALES DE BIOLOGIE CLINIQUE, 2020, 78 (01) : 35 - 46
  • [22] Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A
    Nemes, L.
    Pollmann, H.
    Becker, T.
    HAEMOPHILIA, 2012, 18 (04) : 496 - 502
  • [23] A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII
    Dube, E.
    Bonnefoy, A.
    Merlen, C.
    Castilloux, J. -F.
    Cloutier, S.
    Demers, C.
    Sabapathy, C. A.
    St Louis, J.
    Vezina, C.
    Warner, M.
    Rivard, G. -E.
    HAEMOPHILIA, 2018, 24 (02) : 236 - 244
  • [24] Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)
    Bacon, C. L.
    Singleton, E.
    Brady, B.
    White, B.
    Nolan, B.
    Gilmore, R. M.
    Ryan, C.
    Keohane, C.
    Jenkins, P. Vince
    O'Donnell, J. S.
    HAEMOPHILIA, 2011, 17 (03) : 407 - 411
  • [25] Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events
    Hsia, C. C.
    Zurawska, J. H.
    Tong, M. Z. Y.
    Eckert, K.
    McAlister, V. C.
    Chin-Yee, I. H.
    TRANSFUSION MEDICINE, 2009, 19 (01) : 43 - 49
  • [26] SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A
    Tiede, Andreas
    Allen, Geoffrey
    Bauer, Alexander
    Chowdary, Pratima
    Collins, Peter
    Goldstein, Brahm
    Jiang, Hongyu Jeanne
    Kock, Kathleen
    Takacs, Istvan
    Timofeeva, Margarita
    Wolfsegger, Martin
    Srivastava, Shouryadeep
    HAEMOPHILIA, 2020, 26 (01) : 47 - 55
  • [27] Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
    Lorenzoni, Valentina
    Triulzi, Isotta
    Turchetti, Giuseppe
    BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [28] Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
    Curry, Nicola
    Albayrak, Canan
    Escobar, Miguel
    Holme, Pal Andre
    Kearney, Susan
    Klamroth, Robert
    Misgav, Mudi
    Negrier, Claude
    Wheeler, Allison
    Santagostino, Elena
    Shima, Midori
    Landorph, Andrea
    Tonder, Sidsel Marie
    Lentz, Steven R.
    HAEMOPHILIA, 2019, 25 (03) : 373 - 381
  • [29] Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study
    Mahlangu, Johnny
    Karim, Faraizah Abdul
    Stasyshyn, Oleksandra
    Korczowski, Bartosz
    Salazar, Blanca
    Lucas, Samantha
    Suen, Amy
    Goldstein, Brahm
    Chung, Thomas
    Pabinger, Ingrid
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (02)
  • [30] BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies
    Shah, A.
    Coyle, T.
    Lalezari, S.
    Fischer, K.
    Kohlstaedde, B.
    Delesen, H.
    Radke, S.
    Michaels, L. A.
    HAEMOPHILIA, 2018, 24 (05) : 733 - 740
1234